사카로마이세스 보울라디 관련 클로스트리디오이데스 디피실 감염(CDI)

B 근거 적어도 하나의 무작위 시험이 이를 지지하며, 대체로 일관된 결과를 보입니다.

메타분석에서 표준 항생제 치료의 보조요법으로 사용 시 사카로마이세스 보울라디가 CDI 재발을 50~60% 감소시키는 것으로 나타났습니다. 재발성 CDI 예방에 대해 가장 강력한 근거입니다.

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dsaccharomyces\u002Dboulardii\u0026condition\u003Dclostridioides\u002Ddifficile'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

결론

Key Study Findings

Review

The evidence for probiotics in the treatment of digestive disorders in the pediatric population.

Dose: None vs: None Outcome: None 효과: None None

대상 집단: Pediatric population

Review

Clostridioides difficile Infections: Prevention and Treatment Strategies.

Dose: None vs: None Outcome: C. difficile infection treatment outcomes 효과: None None

대상 집단: Patients with C. difficile infection

Review 520 weeks

Qualitative Analysis of the Efficacy of Probiotic Strains in the Prevention of Antibiotic-Associated Diarrhea.

Dose: None vs: None Outcome: None 효과: None None

대상 집단: None

Review

Clostridium difficile Colitis Prevention and Treatment.

Dose: None vs: None Outcome: Diarrhea outcomes 효과: None None

대상 집단: None

Systematic Review n=228

Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis.

Dose: None vs: None Outcome: Diarrhea outcomes 효과: None None

대상 집단: None

Review

Probiotics in Gastroenterology: How Pro Is the Evidence in Adults?

Dose: None vs: None Outcome: GI condition outcomes (C. diff, AAD, H. pylori) 효과: None None

대상 집단: Adults with GI conditions

Key Statistics

연구

3000

참여자

↑

Positive

등급

Referenced Papers

The evidence for probiotics in the treatment of digestive disorders in the pediatric population. Review

Journal of gastroenterology … 2025 10 인용

Clostridioides difficile Infections: Prevention and Treatment Strategies. Review

Advances in experimental … 2024 2 인용

Qualitative Analysis of the Efficacy of Probiotic Strains in the Prevention of Antibiotic-Associated Diarrhea. Review

Cureus 2023 5 인용

Clostridium difficile Colitis Prevention and Treatment. Review

Advances in experimental … 2019 17 인용

Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis. Other

Frontiers in medicine 2018 450 인용

Probiotics and antibiotic-associated diarrhea in children: A review and new evidence on Lactobacillus rhamnosus GG during and after antibiotic treatment. Review

Pharmacological research 2018 132 인용

Probiotics in Gastroenterology: How Pro Is the Evidence in Adults? Review

The American journal … 2018 46 인용

Probiotics for gastrointestinal disorders: Proposed recommendations for children of the Asia-Pacific region. Review

World journal of … 2017 68 인용

Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. Meta-Analysis

Journal of pediatric … 2016 233 인용

Influence of Saccharomyces boulardii CNCM I-745on the gut-associated immune system. Review

Clinical and experimental … 2016 82 인용

Saccharomyces boulardii to Prevent Antibiotic-Associated Diarrhea: A Randomized, Double-Masked, Placebo-Controlled Trial. Other

Open forum infectious … 2016 58 인용

Probiotics for the Primary and Secondary Prevention of C. difficile Infections: A Meta-analysis and Systematic Review. Review

Antibiotics (Basel, Switzerland) 2015 104 인용

Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children. Review

Nutrition in clinical … 2015 31 인용

Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial. RCT

The American journal … 2012 104 인용

Saccharomyces boulardii and antibiotic-associated diarrhea: effectiveness of prophylactic use. Other

The American journal … 2012 5 인용

Probiotics for prevention and treatment of diarrhea. Review

Journal of clinical … 2011 432 인용

Probiotics. Review

American journal of … 2010

Probiotics as prevention and treatment for diarrhea. Review

Current opinion in … 2009 82 인용

Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Meta-Analysis

The American journal … 2006 918 인용

Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea. Review

Journal of clinical … 2006 112 인용

Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study. RCT

Medical science monitor … 2006

Protection from gastrointestinal diseases with the use of probiotics. Review

The American journal … 2001 648 인용

Treatment and prevention of antibiotic associated diarrhea. Review

International journal of … 2000 181 인용

Mechanisms and management of antibiotic-associated diarrhea. Review

Clinical infectious diseases … 1998 346 인용

Pharmaceutical probiotics for the treatment of anaerobic and other infections. Other

Anaerobe 1997 40 인용

Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. CCT

Gastroenterology 1989 418 인용

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

일반적으로 사용되는 용량

general:: 250-500 mg/day (equivalent to 5-10 billion CFU)
aadprevention:: 500 mg/day (start with antibiotic, continue 7 days after)
cdiffprevention:: 500 mg twice daily as adjunct to standard therapy
travelersdiarrhea:: 250-500 mg/day starting 5 days before travel

상한량: Well-tolerated up to 1,000 mg/day in clinical trials

연구에서 사용된 용량

용량	기간	효과	N
None	--	Mixed	--
None	--	Positive	--
None	520 weeks	Positive	--
None	--	Mixed	--
None	--	Mixed	228
None	--	Mixed	--
None	--	Mixed	--
None	--	Mixed	--

권장 복용 시간: Can be taken with or without food; space 2 hours from antifungals

Safety & Side Effects

보고된 부작용

⚠ Mild gas and bloating
⚠ Rare: fungemia in critically ill patients with central venous catheters
⚠ Thirst (yeast may increase water requirements)
⚠ Very rare: potential environmental contamination risk in ICU settings

알려진 상호작용

● Antifungal medications (may kill S. boulardii, reducing effectiveness)
● Monoamine oxidase inhibitors (S. boulardii contains tyramine)
● Immunosuppressants (theoretical risk of fungemia in immunocompromised patients)

일일 최대 섭취 허용량: Well-tolerated up to 1,000 mg/day in clinical trials

건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.

Frequently Asked Questions

Does 사카로마이세스 보울라디 help with 클로스트리디오이데스 디피실 감염(CDI)?

Based on 6 studies with 3,000 participants, there is moderate evidence from clinical studies that 사카로마이세스 보울라디 may support 클로스트리디오이데스 디피실 감염(CDI) management. Our evidence grade is B (Good Evidence).

How much 사카로마이세스 보울라디 should I take for 클로스트리디오이데스 디피실 감염(CDI)?

Studies have used various dosages. A commonly studied range is 250-500 mg/day (equivalent to 5-10 billion CFU). Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of 사카로마이세스 보울라디?

Reported side effects may include Mild gas and bloating, Rare: fungemia in critically ill patients with central venous catheters, Thirst (yeast may increase water requirements), Very rare: potential environmental contamination risk in ICU settings. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for 사카로마이세스 보울라디 and 클로스트리디오이데스 디피실 감염(CDI)?

We rate the evidence as Grade B (Good Evidence). This rating is based on 6 peer-reviewed studies with 3,000 total participants. The overall direction of effect is positive.

사카로마이세스 보울라디 다른 건강 상태에 대한 근거

항생제 관련 설사(AAD) A 여행자 설사 B

한눈에 보기

Evidence Strength72%

High confidence

연구 분석

RCT (2)Meta (2)Other (2)

대안 비교

이 건강 상태에 대한 다른 성분의 비교 결과를 확인하세요.

모든 성분 보기: 클로스트리디오이데스 디피실 감염(CDI)

자세히 알아보기

References

[1] Kok-Ann Gwee et al.. J Gastroenterol Hepatol. 2025. The evidence for probiotics in the treatment of digestive disorders in the pediatric population. doi:10.1111/jgh.16809 PubMed
[2] Elvira Ingrid Levy et al.. Adv Exp Med Biol. 2024. Clostridioides difficile Infections: Prevention and Treatment Strategies. doi:10.1007/978-3-031-58572-2_11 PubMed
[3] Nyier W Doar et al.. Cureus. 2023. Qualitative Analysis of the Efficacy of Probiotic Strains in the Prevention of Antibiotic-Associated Diarrhea. doi:10.7759/cureus.40261 PubMed
[4] Meltem Dinleyici et al.. Adv Exp Med Biol. 2019. Clostridium difficile Colitis Prevention and Treatment. doi:10.1007/5584_2018_322 PubMed
[5] Lynne V McFarland et al.. Front Med (Lausanne). 2018. Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis. doi:10.3389/fmed.2018.00124 PubMed
[6] Cecilia Mantegazza et al.. Pharmacol Res. 2018. Probiotics and antibiotic-associated diarrhea in children: A review and new evidence on Lactobacillus rhamnosus GG during and after antibiotic treatment. doi:10.1016/j.phrs.2017.08.001 PubMed
[7] Ronald L Koretz. Am J Gastroenterol. 2018. Probiotics in Gastroenterology: How Pro Is the Evidence in Adults? doi:10.1038/s41395-018-0138-0 PubMed
[8] Donald Cameron et al.. World J Gastroenterol. 2017. Probiotics for gastrointestinal disorders: Proposed recommendations for children of the Asia-Pacific region. doi:10.3748/wjg.v23.i45.7952 PubMed
[9] Hania Szajewska et al.. J Pediatr Gastroenterol Nutr. 2016. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. doi:10.1097/MPG.0000000000001081 PubMed
[10] Heike Stier et al.. Clin Exp Gastroenterol. 2016. Influence of Saccharomyces boulardii CNCM I-745on the gut-associated immune system. doi:10.2147/CEG.S111003 PubMed
[11] Stephan Ehrhardt et al.. Open Forum Infect Dis. 2016. Saccharomyces boulardii to Prevent Antibiotic-Associated Diarrhea: A Randomized, Double-Masked, Placebo-Controlled Trial. doi:10.1093/ofid/ofw011 PubMed
[12] Lynne V McFarland. Antibiotics (Basel). 2015. Probiotics for the Primary and Secondary Prevention of C. difficile Infections: A Meta-analysis and Systematic Review. doi:10.3390/antibiotics4020160 PubMed
[13] Danielle Barnes et al.. Nutr Clin Pract. 2015. Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children. doi:10.1177/0884533615610081 PubMed
[14] Pietro Pozzoni et al.. Am J Gastroenterol. 2012. Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial. doi:10.1038/ajg.2012.56 PubMed
[15] Maria Assunta Zocco et al.. Am J Gastroenterol. 2012. Saccharomyces boulardii and antibiotic-associated diarrhea: effectiveness of prophylactic use. doi:10.1038/ajg.2012.222 PubMed
[16] Stefano Guandalini. J Clin Gastroenterol. 2011. Probiotics for prevention and treatment of diarrhea. doi:10.1097/MCG.0b013e3182257e98 PubMed
[17] Nancy Toedter Williams. Am J Health Syst Pharm. 2010. Probiotics. doi:10.2146/ajhp090168 PubMed
[18] Alfredo Guarino et al.. Curr Opin Gastroenterol. 2009. Probiotics as prevention and treatment for diarrhea. doi:10.1097/MOG.0b013e32831b4455 PubMed
[19] Lynne V McFarland. Am J Gastroenterol. 2006. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. doi:10.1111/j.1572-0241.2006.00465.x PubMed
[20] Jeffry A Katz. J Clin Gastroenterol. 2006. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea. doi:10.1097/00004836-200603000-00017 PubMed
[21] Mehmet Can et al.. Med Sci Monit. 2006. Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study. PubMed
[22] P R Marteau et al.. Am J Clin Nutr. 2001. Protection from gastrointestinal diseases with the use of probiotics. doi:10.1093/ajcn/73.2.430s PubMed
[23] E Bergogne-Bérézin. Int J Antimicrob Agents. 2000. Treatment and prevention of antibiotic associated diarrhea. doi:10.1016/s0924-8579(00)00293-4 PubMed
[24] C Högenauer et al.. Clin Infect Dis. 1998. Mechanisms and management of antibiotic-associated diarrhea. doi:10.1086/514958 PubMed
[25] L V McFarland et al.. Anaerobe. 1997. Pharmaceutical probiotics for the treatment of anaerobic and other infections. doi:10.1006/anae.1996.0062 PubMed
[26] C M Surawicz et al.. Gastroenterology. 1989. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. doi:10.1016/0016-5085(89)91613-2 PubMed

FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.

사카로마이세스 보울라디 관련 클로스트리디오이데스 디피실 감염(CDI)

Embed This Widget

결론

Key Study Findings

Key Statistics

Referenced Papers

Dosage & Usage

일반적으로 사용되는 용량

연구에서 사용된 용량

Safety & Side Effects

보고된 부작용

알려진 상호작용

Frequently Asked Questions

Related Evidence

사카로마이세스 보울라디 다른 건강 상태에 대한 근거

References